The Zhitong Finance App learned that according to the Hong Kong Stock Exchange's disclosure on January 1, Jingze Biopharmaceuticals (Hefei) Co., Ltd. (abbreviation: Jingze Biotech) submitted a listing application to the main board of the Hong Kong Stock Exchange, with CICC and Guoyuan International as co-sponsors. The company submitted a statement to the Hong Kong Stock Exchange on June 27, 2025. According to the prospectus, Jingze Biotech is a biopharmaceutical company focusing on the two major tracks of assisted reproductive drugs and ophthalmic drugs. The company has two core products. Among them, JZB30 is a registered recombinant human follicle-stimulating hormone (rhFSH) injection and JZB05 is a candidate drug candidate for anti-vascular endothelial growth factor (VEGF) vitreous injection. In addition, the company also has six pipeline products.

The Zhitong Finance App learned that according to the Hong Kong Stock Exchange's disclosure on January 1, Jingze Biopharmaceuticals (Hefei) Co., Ltd. (abbreviation: Jingze Biotech) submitted a listing application to the main board of the Hong Kong Stock Exchange, with CICC and Guoyuan International as co-sponsors. The company submitted a statement to the Hong Kong Stock Exchange on June 27, 2025. According to the prospectus, Jingze Biotech is a biopharmaceutical company focusing on the two major tracks of assisted reproductive drugs and ophthalmic drugs. The company has two core products. Among them, JZB30 is a registered recombinant human follicle-stimulating hormone (rhFSH) injection and JZB05 is a candidate drug candidate for anti-vascular endothelial growth factor (VEGF) vitreous injection. In addition, the company also has six pipeline products.